期刊文献+

5-氨基-6-氟异吲哚啉-2-羧酸叔丁酯的合成 被引量:2

Synthesis of Tert-Butyl 5-Amino-6-fluoroisoindoline-2-carboxylate
下载PDF
导出
摘要 以5-氨基-6-氟异吲哚啉-1,3-二酮为原料,通过还原、Boc保护,两步反应合成得到5-氨基-6-氟异吲哚啉-2-羧酸叔丁酯。对合成工艺进行了研究,在最佳条件下,两步反应总收率54.7%。产物结构经^(1)H NMR、^(13)C NMR和电喷雾离子源质谱(ESI-MS)表征。 Tert-butyl 5-amino-6-fluoroisoindoline-2-carboxylate was synthesized from 5-amino-6-fluoroisoindoline-1,3-dione through a two-step reaction with a total yield of 54.7%, involving reduction and Boc-protected reaction. The optimal reaction conditions were also investigated. The structure of the product was confirmed by ^(1)H NMR, ^(13)C NMR and electrospray ion source mass spectrometry(ESI-MS).
作者 高县茹 方芙容 李华梅 任习泉 万闽歌 刘斌 Gao Xianru;Fang Furong;Li Huamei;Ren Xiquan;Wan Minge;Liu Bin(School of Pharmacy,Shaanxi Institute of International Trade&Commerce,Collaborative Innovation Center of Green Manufacturing Technology for Traditional Chinese Medicine in Shaanxi Province,Xi'an,Shaanxi 712046,China)
出处 《化学世界》 CAS 2021年第2期101-104,共4页 Chemical World
基金 2019年陕西省大学生创新创业(No.S201913123007) 陕西省教育厅专项科研(No.18JK0954) 陕西省中药绿色制造技术协同创新中心重点培育(No.2019XT-1-05) 陕西国际商贸学院“中药药效物质研究”创新团队(No.SSY18TD01)资助项目。
关键词 5-氨基-6-氟异吲哚啉-2-羧酸叔丁酯 异吲哚啉 还原反应 合成 tert-butyl 5-amino-6-fluoroisoindoline-2-carboxylate isoindoline reduction synthsis
  • 相关文献

参考文献3

二级参考文献50

  • 1高学民,陈月轩,陈伟兴.抗凝药吲哚布芬的合成[J].中国医药工业杂志,1989,20(11):486-487. 被引量:3
  • 2Kondo T., Yoshida K., Yoshimura Y., Tanayama S., Biopharm. Drug Dispos., 1995, 16(9), 755.
  • 3Linden M., Hadler D., Hofmann S., Human Psychopharmacology: Clinical and Experimental, 1997, 12(5), 445.
  • 4Stuk T. L., Assink B. K., Bates R. C., Erdman D. T., Fedij V., Jen- nings S. M., Lassig J. A., Smith R. J., Smith T. L., Organic Process Research & Development, 2003, 7(6), 851.
  • 5Belliotti T. R., Brink W. A., Kesten S. R., Rubin J. R., Wustrow D. J.,Zoski K. T., Whetzel S. Z., Corbin A. E., Pugsley T. A., Heffner T. G., Wise L. D, Bioorganic & Medicinal Chemistry Letters, 1998, 8(12), 1499.
  • 6Zhuang Z. P., Kung M. P., Mu M., Kung H. E, J. Medicinal Chemi- stry, 1998, 41(2), 157.
  • 7Kanamitsu N., Osaki T., Itsuji Y., Yoshimura M., Tsujimoto H., Soga M., Chemical & Pharmaceutical Bulletin, 2007, 55(12), 1682.
  • 8Bernstein P. R., Aharony D., Albert J. S., Andisik D., Barthlow H. G., Bialecki R., Davenport T., Dedinas R. F., Dernbofsky B. T., Koether G., Kosmider B. J., Kirkland K., Ohnmacht C. J., Ports W., Rumsey W. L., Shen L., Shenvi A., Sherwood S., Stollman D., Russell K., Bioorganic & Medicinal Chemistry Letters, 2001, 11(20), 2769.
  • 9Mertens A., Zileh H., Koenig B., Schaefer W., Poll T., Kampe W., Seidel H., Leser U., Leinert H., d. Medicinal Chemistry, 1993, 36(17), 2526.
  • 10Brooklyn V. K., Oreland E. A. G., Danbury S. R. M., Germeting L. W., lsoindolone Compounds, Compositions Containing the Same, and Methods of Use Thereof for the Treatment of Viral Infections Related to the Etiology of Cancer US7705021, 2010.

共引文献4

同被引文献5

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部